Desarrollo de vacunas para la enfermedad de Chagas (CRUZIVAX): preferencias de las partes interesadas y posibles impactos en la asistencia sanitaria

Ramponi, Francesco, Aerts, Céline, Sartor, Paula, Pinazo, María Jesús, Freilij, Héctor, Guzmán, Carlos A., Malchiodi, Emilio and Sicuri, Elisa ORCID: 0000-0002-2499-2732 (2023) Desarrollo de vacunas para la enfermedad de Chagas (CRUZIVAX): preferencias de las partes interesadas y posibles impactos en la asistencia sanitaria. Gaceta Sanitaria, 37. ISSN 0213-9111

Text (Development of vaccines for Chagas disease (CRUZIVAX)) - Published Version Available under License Creative Commons Attribution. Download (186kB)

• Author

Abstract

A vaccine for Chagas disease does not currently exist. This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs. Discrete choice experiments will be employed to estimate and characterize the theoretical demand for the vaccines and investigate patients’ and policy makers’ preferences. Health-related quality of life will be assessed using the EQ-5D-3L questionnaire. Resources use and costs associated with Chagas disease will be investigated using information from the databases of the Hospital Clínic of Barcelona.

Item Type:	Article
Additional Information:	© 2022 The Author(s).
Divisions:	LSE Health
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited:	20 Jan 2023 17:30
Last Modified:	18 Nov 2024 18:27
URI:	http://eprints.lse.ac.uk/id/eprint/117971

Actions (login required)

View Item